Research programme: antiresorptive bone cancer therapy - Auxeris
Alternative Names: AUX-201; AUX-202Latest Information Update: 26 Mar 2007
At a glance
- Originator Auxeris Therapeutics (CEASED)
- Class
- Mechanism of Action Osteoclast inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bone cancer
Most Recent Events
- 27 Aug 2003 Preclinical trials in Bone cancer in USA (unspecified route)